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Dental implantation is an effective standard treatment modality to restore missing teeth and maxillofacial defects. However, in 
diabetics there is an increased risk for implant failure due to impaired peri-implant osseous healing. Early topical insulin treat-
ment was recently shown to normalize diabetic bone healing by rectifying impairments in osteoblastic activities. In this study, 
insulin/poly(lactic-co-glycolic acid) (PLGA) microspheres were prepared by a double-emulsion solvent evaporation method. 
Microspheres were then incorporated in fibrin gel to develop a local drug delivery system for diabetic patients requiring im-
plant treatment. In vitro release of insulin from fibrin gel loaded with these microspheres was assessed, and sustained pro-
longed insulin release over 21 days ascertained. To assess the bioactivity of released insulin and determine whether slow re-
lease might improve impaired diabetic bone formation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
alkaline phosphatase (ALP) activity, mineralized nodule formation, and ELISA (enzyme-linked immunosorbent assay) assays 
were performed. The insulin released from the drug delivery system stimulated cell growth in previously inhibited cells, and 
ameliorated the impaired bone-forming ability of human MG-63 cells under high glucose conditions. Fibrin gel loaded with 
insulin/PLGA microspheres shows potential for improving peri-implant bone formation in diabetic patients. 
insulin, controlled release, peri-implant bone formation, diabetes, hyperglycemia, human MG-63 cells, osteoblastic ac-
tivity 
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During the past decade, dental implant therapy has evolved 
into one of the major treatment modalities for the rehabilita-
tion of missing or lost teeth, and maxillofacial defects with 
high predictability [1]. However, in patients with diabetes 
mellitus such implants are associated with a higher failure 
rate compared with the general population [2–4]. Diabetes 
mellitus is a metabolic disorder characterized by an increase 
in plasma glucose levels with a wide range of systemic 
complications, including myopathy, nephropathy, retinopa-
thy, microvascular and macrovascular disease, altered 
wound and bone healing and periodontitis [5–8]. The asso-
ciation between diabetes mellitus and impaired bone repair 
around endosseous implants and delayed osseointegration 
has been documented in experimental settings [9–11]. In 
addition to impaired biomechanical properties of the frac-
ture callus, diabetes leads to reduced cellular proliferation, 
decreased bony content and inhibited mineralization in os-
seous healing [12,13]. This may contribute to retarded osse-
ointegration of dental implants and increased implant failure 
rates in diabetic patients.  
Insulin has been proposed as being an anabolic agent for 
bone [14], and appears to play a key role in regulating frac-
ture healing [12,15] and peri-implant bone repair [10] in 
diabetes mellitus. Studies have shown that insulin can in-
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fluence bone growth by directly binding to its receptors 
presented on osteoblasts [16,17]. With in vitro bone cell 
cultures, insulin has been shown to stimulate osteoblast pro-
liferation, collagen synthesis, alkaline phosphatase produc-
tion and mineralization [16,18]. In diabetic rats, insulin de-
livered at the fracture site could normalize cellular prolifer-
ation, chondrogenesis, mineralization, cartilage content and 
biomechanical properties of the fracture callus without af-
fecting systemic blood glucose parameters [13]. Conse-
quently, it is rational to develop a drug delivery system for 
local delivery of insulin to ameliorate impaired bone for-
mation around implants, improve surgical osseointegration 
and enhance the success rates of dental implants in diabetic 
patients.  
Poly(lactic-co-glycolic acid) (PLGA), a bioresorbable 
polymer with good biocompatibility, has been frequently 
utilized as a carrier material for sustained delivery of pro-
teins or peptides [19,20]. Sustained-release formulations of 
insulin prepared with PLGA have been reported by some 
investigators as a potential treatment for type 1 diabetes 
mellitus [21,22]. Recently, Wang et al. encapsulated insulin 
inside PLGA microspheres and directly delivered the pul-
verized microspheres to the implant–bone interface in dia-
betic rats [23]. The implant-bone contact was improved by 
direct infiltration of insulin in the diabetic rats, but was still 
less than that of non-diabetic rats. Potentially, local admin-
istration of microspheres around the implants may display 
drug loss [24], which could reduce the active effect of the 
sustained-release drug on the osseointegration of dental 
implants. Other disadvantages, such as inconvenience dur-
ing the operation, are also obstacles to clinical use of the 
local application of microspheres to improve osseointegra-
tion. 
Fibrin gel, approved by the FDA for clinical use as a 
sealant, is a non-cytotoxic, fully-resorbable, biocompatible 
matrix and has been used as a carrier to deliver growth fac-
tors [25,26]. However, fibrin gel is not applicable for use as 
a long-term drug delivery system because of its insufficient 
duration of delivery [27]. Fibrin gels loaded with nanoparti-
cles or nanospheres have been developed to achieve a more 
sustained release of bioactive agents than nanoparticles, 
nanospheres or fibrin gel alone [28,29]. Moreover, com-
mercially available fibrin gel, which is a two-component 
system, is injectable. The gel can be delivered through a 
supplied applicator holding two liquid components in sepa-
rate syringes, providing concurrent mixing and delivery. In 
addition, it can gel in situ within a few seconds of injection. 
Therefore, fibrin gel loaded with microspheres may act as a 
convenient drug delivery system for sustained release of 
insulin around implants. 
We have established a novel drug delivery system by in-
corporating insulin/PLGA microspheres into fibrin gel. 
These have the potential to promote peri-implant bone for-
mation in diabetes. Insulin/PLGA microspheres were pre-
pared using the water-in-oil-in-water (W/O/W) double- 
emulsion method. These microspheres were incorporated 
into fibrin gel and insulin release kinetics evaluated in vitro. 
Bioactivity and pharmacological properties of the released 
insulin were investigated in cultured cells.  
1  Materials and methods 
1.1  Materials 
PLGA (75:25, Mw 15 kD) was synthesized and kindly pro-
vided by the School of Life Science and Engineering, 
Southwest Jiaotong University (Chengdu, China). Bovine 
insulin and polyvinylalcohol (PVA) were obtained from 
Sigma (St. Louis, MO, USA), and insulin was used without 
further purification. A commercially available fibrin glue kit 
was purchased from Guangzhou Bioseal Biotech Co., Ltd. 
(Guangzhou, China). Minimum essential medium with 
Earle’s balanced salts (MEM/EBSS) and heat-inactivated 
fetal bovine serum (FBS) were purchased from Hyclone 
(Logan, UT, USA). MEM nonessential amino acids (NEAA) 
were from Gibco (Grand Island, NV, USA). Trypsin from 
porcine pancreas, MTT and alizarin red S were from Sigma. 
Human collagen type I ELISA kit was from R&D (Minne-
apolis, MN, USA). All other chemicals were of the highest 
grade commercially available. 
1.2  Preparation of insulin/PLGA microspheres  
Insulin/PLGA microspheres were prepared by the dou-
ble-emulsion solvent evaporation method (W/O/W). Briefly, 
3 mg of lyophilized insulin powder was dissolved in 100 μL 
0.01 N HCl, and the pH adjusted to 4.0. Aqueous insulin 
solution (100 μL, 30 mg mL1) was mixed with 1 mL of 
dichloromethane (DCM) containing 100 mg of PLGA, then 
ultra-sonicated (SCIENTZ-2D, SCIENTZ, Ningbo, China) 
at an energy output level of 20% in an ice bath for 2 min. 
The primary emulsion was then re-emulsified with 10 mL 
of 1% PVA aqueous solution using a homogenizer (RW 
20.n, IKA, Shanghai, China) at 1500 r min1 for 5 min. The 
W/O/W emulsion was poured into 10 mL of PVA aqueous 
solution and stirred at 500 r min1 for 8 h at room tempera-
ture, allowing the DCM to evaporate. The emulsion gradu-
ally solidified as the solvent diffused from the emulsion 
droplets into the external phase. The resulting microspheres 
were washed and collected by filtration, sieving, centrifuga-
tion (TDZ5-WS, Xiangyi, Changsha, China) and lyophiliza-
tion.  
1.3  Microsphere characterization  
The surface morphology of the insulin/PLGA microspheres 
was examined and photographed using a scanning electron 
microscope (S800, Hitachi, Tokyo, Japan). Samples were 
coated with gold palladium under vacuum using an 
ion-coater to achieve a film of 20 nm thickness. Particle size 
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distribution was determined by laser diffractometry using a 
laser sizer (OMEC-15000, OMEC, Zhuhai, China). 
1.4  Determination of insulin loading and encapsulation 
efficiency of microspheres  
The amount of encapsulated insulin in the microspheres was 
determined after extraction with CH3CN and 0.01 N HCl 
using HPLC. Samples (20 µL) were injected into a chro-
matograph (LC-10AT VP, Shimadzu, Kyoto, Japan) 
equipped with an ultraviolet detector (SPD-10A VP, Shi-
madzu) and an Apollo C-18 column (150 mm×4.6 mm in-
ternal diameter, 5 μm, 100 Å) (Alltech, Deerfield, IL, USA). 
The mobile phase was a mixture of 27% acetonitrile and 
73% buffer containing 0.2 mol L1 NaHSO4 adjusted to pH 
2.3 with phosphoric acid. The flow rate was 1.0 mL min1, 
with the wavelength set at 214 nm. Insulin loading was ex-
pressed as percentage of amount of encapsulated insulin per 
unit dry weight of microspheres. The theoretical drug con-
tent was obtained under the assumption that the entire 
amount of drug was encapsulated with no drug loss at any 
stage of microsphere preparation. The encapsulation effi-
ciency was calculated using the following formula: (meas-
ured insulin loading/theoretical insulin loading)×100%. 
1.5  Preparation of fibrin gel loaded with insulin/PLGA 
microspheres  
The fibrin glue kit was composed of lyophilized fibrinogen 
powder, lyophilized thrombin powder, potassium dihydro-
gen phosphate (KDP) solution and calcium chloride (CaCl2) 
solution. Fibrin gel loaded with insulin/PLGA microspheres 
was prepared by dissolving lyophilized fibrinogen powder 
in 0.5 mL of KDP solution to obtain a mixture containing 
12.5 mg of fibrinogen. Lyophilized thrombin powder was 
dissolved in 0.5 mL of 40 mmol L1 CaCl2 solution, then 10 
mg of insulin/PLGA microspheres was added to form a 
suspension containing 80 IU of thrombin. Finally, the mix-
ture and the suspension were loaded into the supplied ap-
plicator, which held the two components in separate syring-
es and provided simultaneous mixing and delivery, forming 
a fibrin clot on delivery.  
1.6  In vitro kinetics of insulin release  
Insulin release from PLGA microspheres was determined 
by suspending microspheres in 1 mL of phosphate buffer 
(pH 7.4) as 20% (w/v) dispersion in a centrifuge tube. The 
tubes were placed in an incubator-shaker at 37°C and agi-
tated at approximately 50 r min1. At designated sampling 
times (1, 3, 5, 7, 10, 14, 18, 21 and 24 d), the supernatant 
was completely withdrawn after centrifugation and replaced 
with fresh media. HPLC analysis of the supernatant was 
performed to determine the amount of insulin released from 
the microspheres. 
In vitro release kinetics of insulin from fibrin clots con-
taining insulin/PLGA microspheres or fresh insulin was 
determined as follows: samples (1 mL) containing 10 mg of 
microspheres or the equivalent amount of fresh insulin as 
the encapsulated insulin were polymerized in centrifuge 
tubes containing 2 mL of phosphate buffer (pH 7.4). The 
samples were incubated at 37°C and agitated continuously. 
Supernatant was removed at prescribed times (1, 3, 5, 7, 10, 
14, 18, 21 and 24 d) and replenished with fresh media. The 
amount of insulin released was estimated using HPLC.  
1.7  Human MG-63 cell cultures  
Human MG-63 cells were kindly provided by the Tumor 
Research Institute of the Chinese Academy of Medical Sci-
ence (Beijing, China). Cells were cultured in T75 flasks 
(Sigma-Aldrich, St. Louis, MO, USA) containing 10 mL of 
MEM/EBSS supplemented with NEAA and 10% FBS at 
37°C/5% CO2. When the cells reached 80%–90% conflu-
ence, the medium was aspirated and cells were washed 
twice with 10 mL of PBS. Cells were then detached with 2 
mL of 0.25% trypsin and EDTA solution, and incubated for 
2 min. Trypsin neutralization was carried out with 1 mL of 
FBS and 7 mL of PBS. Cells were then centrifuged (1500 r 
min1, 5 min) followed by resuspension in 10 mL of fresh 
media. Cells were counted by removing 10 μL of cell sus-
pension and combining it with an equal volume of trypan 
blue solution. This mixture was vortexed and a sample 
loaded into a hemocytometer chamber, with cells counted 
using an inverted microscope (DMIL, LEICA, Solms, Ger-
many). 
1.8  Insulin bioactivity and the effect of insulin on os-
teoblasts under high glucose 
1.8.1  MTT assays 
The human MG-63 cell suspensions were diluted to 10000 
cells mL1 in MEM/EBSS containing 10% FBS and seeded 
onto 96-well plates to a final well volume of 200 μL (2000 
cells/well). After culturing for 24 h, the cells were se-
rum-starved overnight in serum-free MEM/EBSS. The me-
dium was then exchanged, and cells treated with one of the 
following media: (a) MEM/EBSS containing NEAA, 5% 
FBS and 5.5 mmol L1 glucose (normal glucose, NG); (b) 
MEM/EBSS containing NEAA, 5% FBS and 25 mmol L1 
glucose (high glucose, HG); (c) MEM/EBSS containing 
NEAA, 5% FBS, 25 mmol L1 glucose and 100 nmol L1 
fresh insulin; (d) MEM/EBSS containing NEAA, 5% FBS, 
25 mmol L1 glucose and 100 nmol L1 insulin released 
from fibrin gel loaded with insulin/PLGA microspheres; 
and (e) MEM/EBSS containing NEAA, 5% FBS, 25 mmol 
L1 glucose and supernatant from fibrin gel loaded with 
placebo PLGA microspheres. Supernatant samples from 
release experiments of fibrin gel loaded with insulin/PLGA 
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microspheres or placebo PLGA microspheres were taken on 
days 1, 7, 14 and 21, and diluted with MEM/EBSS contain-
ing NEAA. After culturing for 3 d, 20 μL of MTT was 
added to each well and incubated for 4 h at 37°C. Subse-
quently, the supernatants were removed; and the formazan 
crystals that had formed were solubilized with 150 μL of 
dimethylsulfoxide. The absorbance value of each well was 
read at 490 nm using an ELx800uv reader (Bio-Tek, 
Winooski, VT, USA). 
1.8.2  ALP activity assay 
Cell suspensions were diluted to 200000 cells mL1 in 
MEM/EBSS containing 10% FBS and seeded onto 24-well 
plates to a final well volume of 1 mL. The cells were se-
rum-starved overnight and then incubated with the 
above-described media separately for 7 d. Aliquots of su-
pernatants from release experiments of the fibrin gel loaded 
with either insulin/PLGA microspheres or placebo PLGA 
microspheres were taken on days 1 and 5, and diluted with 
MEM/EBSS containing NEAA. Cells were initially incu-
bated with media containing supernatant from day 1 for 4 d. 
To this were then added media containing supernatant from 
day 5, the whole being incubated a further 3 d. On day 7, 
culture supernatants were aspirated and ALP activity meas-
ured by an automatic biochemical analyzer (BS300, Min-
dray, Shenzhen, China). 
1.8.3  ELISA assay for the secretion of type I collagen 
Cells were treated as above and the culture supernatants 
were withdrawn on day 7. The amount of type I collagen in 
the culture supernatant was determined using the human 
collagen type I ELISA kit according to the manual provided 
by the manufacturer.  
1.8.4  Assay of mineralized nodule formation 
Cells were seeded onto 24-well plates as above and se-
rum-starved overnight. Subsequently, the cells were incu-
bated with the five above-described media separately for 21 
d. Supernatant samples were taken on days 1, 5, 7, 10, 14 
and 18. Cultured cells were treated as above (ALP activity 
assay) for the first 7 days. Thereafter, at the corresponding 
time point the culture media were replaced with me-
dia-containing supernatant samples taken from the matching 
time point, i.e., the media-containing supernatant samples 
taken from day 7 of release experiments were added into 
plates on day 7 of cell culture and so on. The mineralized 
nodule formation was evaluated by alizarin red-S staining. 
Cells were rinsed twice with PBS followed by fixation with 
95% ethanol for 15 min at room temperature. Cells were 
then stained with 1% alizarin red S (pH 8.3) for 10 min at 
room temperature and rinsed three times with 50% ethanol. 
For quantification, the bound staining was eluted with 10% 
(w/v) cetylpyridinium chloride, and the absorbance value of 
the supernatants measured at 490 nm using an ELx800uv 
reader. 
1.9  Statistical analysis  
The software package SPSS 16.0 (Chicago, IL, USA) was 
used for statistical analysis. All data are presented as 
means±SD and P<0.05 was considered statistically signifi-
cant. The results were evaluated by one way analysis of 
variance (ANOVA), with a least significant difference (LSD) 
test for post-hoc analyses. All experiments were repeated at 
least three times, and representative experiments are shown. 
2  Results  
2.1  Surface morphology, particle size and encapsula-
tion efficiency of microspheres  
Insulin/PLGA microspheres were a white powder. Under 
SEM, the microspheres were shown to be spherical with a 
smooth surface texture (Figure 1). The particle diameter of 
the insulin/PLGA microspheres was (31.2±15.7) μm. Their 
encapsulation efficiency determined over three replicates 
was 61.1%±4.3%. 
2.2  In vitro kinetics  
Microspheres were incorporated into fibrin gel and in vitro 
release behaviors were investigated. The cumulative release 
rate of insulin from fibrin gel loaded with PLGA micro-
spheres in PBS was determined using HPLC and compared 
with those from fibrin gel and insulin/PLGA microspheres 
(Figure 2). In these three systems, the fibrin gel exhibited 
the highest initial burst release of 62% and the shortest re- 
 
 
Figure 1  Morphology of insulin/PLGA microspheres by scanning elec-
tron microscopy.
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Figure 2  Profiles of insulin release from fibrin gel, microspheres and fibrin gel loaded with microspheres (n=3). 
lease length of 5 d. In contrast, an insulin burst release from 
microspheres of approximately 32% was observed within 
the first 24 h, followed by a slow release phase sustained for 
almost 14 d. Compared with these two systems, the fibrin 
gel loaded with PLGA microspheres released insulin in a 
much steadier and more sustained manner. After incorpora-
tion of PLGA microspheres into fibrin gel, the initial burst 
release was decreased to 17% and insulin release was ex-
tended to 21 d. 
2.3  Bioactivity and the effect of released insulin on os-
teoblasts under high glucose 
Bioactivity of released insulin was determined by the MTT 
bioassay using quiescent MG-63 cells and compared with 
the activity of a fresh insulin control at the same concentra-
tion. As shown in Figure 3, high glucose induced a statisti-
cally significant reduction in the proliferation of MG-63 
cells (P<0.001). This inhibition was clearly reversed by the 
addition of either fresh or released insulin (P<0.001). Re-
leased insulin from days 1 and 7 displayed high levels of 
bioactivity, similar to fresh insulin. However, a gradual de-
cline in bioactivity of insulin was observed over the release 
period. Although released insulin on days 14 (P<0.05) and 
21 (P<0.001) partly lost bioactivity, they still induced high-
er MG-63 cell proliferation which was statistically signifi-
cant when compared with the placebo group and matched 
for collection time point (P<0.001). Supernatants from the 
placebo group demonstrated no changes in MG-63 cell 
growth when compared with MG-63 cells under high glu-
cose conditions without any treatment.  
The ALP activity assay and ELISA to detect secretion of 
type I collagen were performed on human MG-63 cells to 
further investigate the bioactivity of released insulin and its 
effect on matrix development. Figure 4 shows that ALP 
activity was clearly decreased under high glucose condi-
tions compared with normal glucose conditions (P<0.001). 
ALP activity was increased significantly in MG-63 cells 
under high glucose conditions after insulin treatment com-
pared with cells under high glucose conditions with no 
treatment (P<0.001). ALP activity for the released insulin 
treatment group was statistically comparable to those for the 
group treated with fresh insulin and the normal glucose 
group. The increased ALP activity for the cells under high 
glucose conditions treated with released insulin was signif-
icantly higher than that of the placebo group (P<0.001). 
Compared with the high glucose group receiving no treat-
ment, no change was observed for the ALP activity of 
MG-63 cells after treatment with supernatants from the pla-
cebo group. The secretion of collagen type I by MG-63 cells 
cultured in different media is shown in Figure 5. The 
amount of collagen type I secreted by MG-63 cells under 
high glucose conditions without any treatment was signifi-
cantly lower than that for the cells under normal glucose 
conditions (P<0.01). After treatment of cells with high lev-
els of glucose and insulin, collagen type I was significantly 
increased (P<0.001), returning to a level equal to that of 
cells under normal glucose conditions. Additionally, there 
was no difference in the secretion of collagen type I be-
tween the cells treated with released insulin or fresh insulin. 
In contrast, MG-63 cells treated with supernatants from the 
placebo group resulted in no change in collagen type I se-
cretion under high glucose pressure. Additionally, the 
amount of collagen type I from the cells treated with super-
natants containing released insulin was significantly higher 
than those of the cells treated with supernatants containing 
no insulin, i.e., the placebo group (P<0.01). 
Calcium deposition was quantified using alizarin red S   
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Figure 3  MTT bioassays to evaluate insulin bioactivity. The effect of insulin released from fibrin gel loaded with insulin/PLGA microspheres into super-
natants sampled on days 1, 7, 14 and 21 in release experiments on osteoblast proliferation in human MG-63 cells under high glucose. Data represent the 
mean±SD, n=8 per group. *, P<0.05, **, P<0.001, compared to the normal glucose group; #, P<0.001, compared to the high glucose group; n.s., not signifi-
cant; †, P<0.05, ††, P<0.001, released insulin compared to fresh insulin; ‡, P<0.001, released insulin compared to placebo matched for the collection time  
point. 
 
Figure 4  ALP activity assays to evaluate insulin bioactivity. The effect 
of insulin released from fibrin gel loaded with insulin/PLGA microspheres 
into supernatants in release experiments on early osteoblastic differentia-
tion and bone forming ability of human MG-63 cells under high glucose. 
Data represent the mean±SD, n=6 per group. *, P<0.001, compared to the 
normal glucose group; #, P<0.001, compared to the high glucose group; 
n.s., not significant, released insulin compared to fresh insulin; †, P<0.001,  
released insulin compared to placebo. 
 
Figure 5  ELISA assay for the secretion of type I collagen to evaluate 
insulin bioactivity. The effect of insulin released from fibrin gel loaded 
with insulin/PLGA microspheres into supernatants in release experiments 
on early osteoblastic differentiation and bone forming ability of human 
MG-63 cells under high glucose. Data represent the mean±SD, n=6 per 
group. *, P<0.05, **, P<0.01, compared to the normal glucose group; #, 
P<0.01, ##, P<0.001, compared to the high glucose group; n.s., not signif-
icant, released insulin compared to fresh insulin; †, P<0.01, released insu- 
lin compared to placebo.
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Figure 6  Assays of mineralized nodule formation to evaluate insulin bioactivity. A, Typical calcified nodules after alizarin red S staining. B, Calcium 
deposition quantified by alizarin red S absorbance. The effect of insulin released from fibrin gels loaded with insulin/PLGA microspheres into supernatants 
in release experiments on late osteoblastic differentiation and bone forming ability of human MG-63 cells under high glucose. Magnification, 200×. Data 
represent the mean±SD, n=6 per group. *, P<0.01, **, P<0.001, compared to the normal glucose group; #, P<0.001, compared to the high glucose group; n.s.,  
not significant, released insulin compared to fresh insulin; †, P<0.001, released insulin compared to placebo. 
staining to investigate the bioactivity of released insulin and 
its effect on matrix mineralization. Typical calcified nodules 
are shown in Figure 6A. Quantitative measurements of aliz-
arin red S absorbance showed that the normal glucose group 
displayed the highest mineralization level, whereas the high 
glucose and placebo groups exhibited the lowest (Figure 
6B). A significant increase was observed in the alizarin red 
S absorbance on applying fresh insulin or released insulin to 
MG-63 cells under high glucose conditions compared with 
the high glucose group receiving no treatment (P<0.001). 
Released insulin improved the mineralization by approxi-
mately the same degree as the fresh insulin. The mineraliza-
tion of the cells treated with fresh insulin was statistically 
comparable with the normal level. However, mineralization 
of the cells treated with released insulin remained below the 
normal level (P<0.01). No significant difference was ob-
served in the mineralization level between the placebo 
group and the high glucose group without any treatment. 
The mineralization level of MG-63 cells treated with su-
pernatants containing released insulin was significantly 
higher than that of cells treated with supernatants containing 
no insulin (P<0.001).  
3  Discussion 
The success of implants relies on the degree of osseointe-
gration [30]. This provides the anchoring of an implant due 
to the growth of bone around it. After implantation, the os-
seous healing around the implant is a relatively complicated 
proliferative, physiological process involving both bone 
formation and resorption. In the healing process, bone for-
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mation by osteoblasts is critical to osseointegration of an 
implant. However, in diabetes mellitus, bone formation is 
decreased, with suppressed osteoblast proliferation, differ-
entiation and bone forming capacity during the critical early 
stage of osseous healing considered a plausible pathogenic 
mechanism [31]. One approach toward ameliorating im-
paired diabetic bone healing is through the topical applica-
tion of insulin at fracture or implant sites [13,23]. In this 
study, we developed a drug delivery system for local insulin 
delivery around implants. First, we encapsulated insulin into 
PLGA microspheres using a W/O/W double-emulsion sol-
vent extraction technique with an encapsulation efficiency 
of 61.1%. The resulting microspheres appeared spherical 
and smooth, with a mean diameter of 31.2 μm. The micro-
spheres were then incorporated into the fibrin gel, the re-
lease profile showing almost full release of insulin over 21 d. 
The MTT bioassay, the ALP activity assay, an ELISA for 
the secretion of type I collagen and the mineralized nodule 
formation assay displayed high levels of sustained bioactiv-
ity for released insulin and a positive effect of released in-
sulin on stimulating retarded diabetic osteoblastic activity.  
Insulin can stimulate the growth of a number of cell 
types, including osteoblasts [18,32]. Moreover, insulin can 
act as an anabolic agent to mediate bone formation directly 
and/or indirectly [14]. After insulin binds to its specific 
high-affinity receptor, the insulin receptor, which is present 
on the surface of the osteoblast, activates downstream sig-
naling cascades, such as the phosphatidylinositol 3-kinase 
and mitogen-activated protein kinase pathways to stimulate 
osteoblast proliferation and differentiation [18]. Insulin 
possesses primary, secondary and tertiary structure with 
labile bonds and side chains with chemically reactive 
groups. Disruption of these structures or modification of 
side chains readily occurs and can result in loss of insulin 
bioactivity [33]. Insulin was therefore encapsulated into 
PLGA microspheres to maintain bioactivity and thus to re-
alize sustained local delivery of bioactive insulin when ad-
ministered to the tissues around implants [23]. However, 
according to published research on the local application of 
PLGA microspheres around implants, the actual operation 
would be inconvenient and drug loss would occur during 
implantation. Wang et al. [23] reported that pulverized mi-
crospheres prepared in advance could be mixed with blood 
and then loaded on the implant surface before insertion into 
the surgically prepared implant osteotomy site. The oste-
otomy site should be drilled to a diameter a little smaller 
than that of the implant to achieve perfect bone to implant 
contact and sufficient implant primary stability, a prerequi-
site for efficient osseointegration [34]. Therefore, micro-
spheres loaded on the implant surface would be scratched 
off due to mechanical friction during implant placement. 
Microspheres could also be administered into the tissue 
surrounding the dental implant after suspension in fresh 
blood until a clot was formed [24]. However, some of the 
microspheres might wash away during implant placement. 
In our unpublished research, fibrin gel loaded with micro-
spheres could be injected with a supplied applicator without 
any drug loss into an implant site properly prepared for a 
perfect bone-to-implant contact and consequent primary 
implant stability. The supplied applicator holds two com-
ponents—a liquid mixture containing fibrinogen and a sus-
pension containing thrombin and microspheres—in separate 
syringes and provides simultaneous mixing and delivery. 
After injection, this drug delivery mixture solidified into a 
semi-rigid gel matrix in situ within several seconds and 
maintained high flexibility for a short period. This ensured 
high initial retention of the drug around implants and suffi-
cient time for implant placement. Therefore, fibrin gel 
loaded with microspheres may serve as a drug delivery sys-
tem for local insulin delivery around implants, which would 
be more applicable to practical use than microspheres alone.  
After insulin/PLGA microspheres were incorporated into 
fibrin gel, a more sustained and controlled release of insulin 
was achieved compared with either insulin/PLGA micro-
spheres or fibrin gel alone. Fibrin gel loaded with insulin 
exhibited a short-term release of insulin with a high initial 
burst release, which may be accounted for by a simple dif-
fusion-controlled mechanism. For PLGA microspheres, 
insulin was released more slowly and steadily. It was known 
that drug release from PLGA microspheres is a complicated 
process. This involves an initial burst release of sur-
face-bound medication, the drug traveling through the in-
terconnecting channels to the surface formed during micro-
sphere hardening, and release due to physical or chemical 
erosion of the polymer. In contrast, the insulin release from 
fibrin gel loaded with PLGA/microspheres was further pro-
longed and stabilized by the combination of two individual 
drug delivery systems. This improvement in the release be-
havior of the newly developed drug delivery system could 
be explained by a combination of mechanisms of insulin 
release from microspheres and insulin diffusion through 
fibrin gel. 
In our study, 5.5 and 25 mmol L1 glucose were used to 
mimic the blood glucose in healthy individuals and in pa-
tients with poorly controlled diabetes, respectively. Our 
results clearly demonstrated profound inhibition in the pro-
liferation, differentiation and bone forming capacity of os-
teoblast-like cells under high glucose conditions, which 
were consistent with previous reports [35–37]. A dose- and 
time-dependent mitogenic response of MG-63 cells to add-
ed insulin under high glucose conditions was confirmed in 
another study in our lab (unpublished data). Insulin bioac-
tivity was tested by the MTT bioassay, which has the ad-
vantage of determining whether the released insulin pre-
serves its bioactivity to induce a biological response in a 
functional biological system compared with other in vitro 
methods, such as HPLC and ELISA. In the present study, 
according to the MTT assay results, the released insulin 
collected during the whole release period significantly stim-
ulated the proliferation of MG-63 cells under high glucose 
956 Han Y, et al.   Sci China Life Sci   November (2012) Vol.55 No.11 
conditions. However, the released insulin exhibited a de-
clining trend in the bioactivity of accelerating osteoblast 
proliferation over the release period. A similar phenomenon 
was reported by Hrynyk et al. [38]. The increasingly acidic 
microenvironment within degrading microspheres may con-
tribute to the loss of insulin bioactivity [39]. Because insulin 
stability is critical for the drug delivery system, further 
studies will be initiated to enhance insulin stability by 
maintaining a near neutral microclimate pH within the de-
grading microsphere during release. 
During bone formation, osteoblasts undergo a series of 
developmental stages, such as proliferation, matrix devel-
opment and matrix mineralization [40]. ALP is expressed 
early in osteoblast development and type I collagen is the 
main component of the bone matrix. Thus ALP activity and 
the secretion of type I collagen could be used as indices to 
evaluate matrix development. Additionally, mineralized 
nodule formation can reflect matrix mineralization. For cells 
under high glucose conditions receiving no treatment, ALP 
production, synthesis of type I collagen and mineralized 
nodule formation were significantly decreased compared 
with cells cultured under normal glucose conditions. Our 
results were in accordance with previous studies [35–37]. 
The addition of released insulin to the culture media stimu-
lated ALP production, type I collagen synthesis and miner-
alized nodule formation, with this high level of bioactivity 
similar to that for fresh insulin. Therefore, while high glu-
cose greatly disrupted the development of osteoblasts and 
retarded osteoblastic activity, having deleterious effects on 
osteoblast differentiation and bone forming activity, the 
continuously released bioactive insulin attenuated these 
effects. Taking these results together with those from the 
MTT bioassay, we demonstrated the direct bioactivity of 
released insulin and indicated the potential for the local ap-
plication of fibrin gel loaded with insulin/PLGA micro-
spheres to improve impaired bone formation around im-
plants in diabetes mellitus. 
Supernatants from placebo groups were also assayed to 
identify any potential biological response to degradation 
products. Supernatants containing released insulin signifi-
cantly stimulated cellular proliferation, promoted ALP ac-
tivity, increased type I collagen synthesis and enhanced 
calcium deposition in human MG-63 cells under high glu-
cose conditions when compared with supernatants from the 
placebo group. Additionally, no significant differences were 
observed between the placebo group and the high glucose 
group receiving no treatment. These data confirmed the 
bioactivity of released insulin and demonstrated that degra-
dation products had no stimulatory effects. 
The above results suggest that fibrin gel loaded with in-
sulin/PLGA microspheres offers great potential to act as a 
drug delivery system for sustained delivery of bioactive 
insulin around dental implants with practical convenience. 
The limited results of this study still allow us to speculate 
that insulin released from the fibrin gel loaded with PLGA 
microspheres may ameliorate impaired peri-implant bone 
formation in diabetes, and thus improve compromised osse-
ointegration. This study justifies continued research in dia-
betic animal models to further investigate the effect of sus-
tained insulin delivery via fibrin gels loaded with insu-
lin/PLGA microspheres around implants on improving pe-
ri-implant bone formation and osseointegration in diabetes. 
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